Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Aug 14;23(16):9108. doi: 10.3390/ijms23169108

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Inhibitory effects of receptor tyrosine kinase (RTK) inhibitors on HGF- and EGF-induced enhancement of UPP1 mRNA expression. HepG2 cells were pretreated with SU11274 (5 µM), a MET inhibitor, erlotinib ((A) 5 µM; B-E, indicated concentration), and gefitinib ((B–E) indicated concentration) 15 min before administration of growth factors, and were continued to be cultured for 7 h after treatment with HGF (50 ng/mL), EGF (50 ng/mL) or both. DMSO, used as vehicle, has no effect on the expression of mRNA. At the end of the incubation period, the expression level of mRNA was measured and was expressed as a percentage of that in cells not treated with growth factors and RTK inhibitors. Each bar represents the mean ± SD of 5 experiments. Significantly different from the level in cells treated with growth factor alone: ** p < 0.01, * p < 0.05.

Inhibitory effects of receptor tyrosine kinase (RTK) inhibitors on HGF- and EGF-induced enhancement of UPP1 mRNA expression. HepG2 cells were pretreated with SU11274 (5 µM), a MET inhibitor, erlotinib ((A) 5 µM; B-E, indicated concentration), and gefitinib ((B–E) indicated concentration) 15 min before administration of growth factors, and were continued to be cultured for 7 h after treatment with HGF (50 ng/mL), EGF (50 ng/mL) or both. DMSO, used as vehicle, has no effect on the expression of mRNA. At the end of the incubation period, the expression level of mRNA was measured and was expressed as a percentage of that in cells not treated with growth factors and RTK inhibitors. Each bar represents the mean ± SD of 5 experiments. Significantly different from the level in cells treated with growth factor alone: ** p < 0.01, * p < 0.05.